Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep716 | Pituitary and Neuroendocrinology | ECE2022

Pituitary Hyperplasia secondary to Severe Primary Hypothyroidism

Esdaile Harriet , Alameri Majid , Alnuaimi Abdulla , Martin Niamh , Meeran Karim

Introduction: Thyrotroph pituitary hyperplasia in context of severe primary hypothyroidism is rare and usually occurs due to loss of thyroxine feedback inhibition and overproduction of thyrotropin-releasing hormone, leading to pituitary gland enlargement. Pituitary hyperplasia caused by primary hypothyroidism responds well to thyroid hormone replacement therapy and rarely requires surgical intervention. Case presentation: A 42-year-old female with backgr...

ea0069oc8 | Oral Communications | SFENCC2020

Bones, Moans and Groans: A Calcium Conundrum

Esdaile Harriet , Lazarus Katharine , Saliu David , Sartori Giulia , Qureshi Asjid

Case history: A 51 year old gentleman presented to ED with severe right thigh pain, a 6 month history of weight loss, and 2 weeks of polyuria. He had no medical history and took no regular medications. He worked as a postman, was a non-smoker and non-drinker.Investigations: Bloods showed adjusted calcium of 5.04 mmol/l, parathyroid hormone (PTH) 1.4 pmol/l, and alkaline phosphatase 438 IU/l. Vitamin D was reported one week later as 37 nmol/l. His haemogl...

ea0062p28 | Poster Presentations | EU2019

Alemtuzumab induced thyrotoxicosis in a patient undergoing autologous haematopoietic stem cell transplant for multiple sclerosis

Esdaile Harriet , Hinton Richard , Sheridan Helena , Rogosic Srdan , Pavlu Jiri , Olavarria Eduardo , Gabriel Ian

Case History: A 37 year old female underwent an elective autologous stem cell transplant (ASCT) for multiple sclerosis (MS), with cyclophosphamide and anti-thymocyte (ATG) conditioning. She had previously received two doses of alemtuzumab, with the last dose 12 months prior to ASCT. Baseline thyroid function was normal pre atemluzumab. 3 months prior to dose 2 (18 months post first dose), subclinical hyperthryoidism was present with a raised TSH antibody (0.08 unit/ml). There ...